The Wellcome Genome Campus is home to some of the world's foremost institutes and organisations in genomics and computational biology committed to delivering life-changing science with the reach, scale, and imagination to solve some of humanity's greatest challenges. The Campus has its roots in the Human Genome Project and over the next 25 years, our vision is for the Campus to become the most important international hub for scientific, business, educational and cultural activities emanating from genomes and biodata. A recently-built BioData Innovation Centre provides rentable spaces for innovative businesses that complement the unique research and science of the Campus.
No data available
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time.
Xampla is a materials innovation company unlocking the power of plants to create natural materials to change the world. Their platform technology powers a variety of applications including microencapsulation to enhance performance and Morro™ materials: world-first materials designed to eliminate the world’s most polluting plastics.
We take our inspiration, and our name, from the principle of exaptation – the concept that a trait which evolved for one purpose can be harnessed to serve an entirely different function.
Using the power of genome editing and synthetic biology, we’ve converted nature’s ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. We’re arming our delivery platform to carry a broad spectrum of therapeutic payloads – cytokines, antibodies, nucleic acids and more. We’ve designed these delivery vehicles to activate only on recognition of their chosen targets, unleashing their powerful cargo with exquisite precision.
We’re developing our multi-modal therapies to treat the most complex of diseases including cancer and autoimmunity.
Using the power of genome editing and synthetic biology, we’ve converted nature’s ultimate first-responder cell into a modular chassis, ready to be programmed to treat disease. We’re arming our delivery platform to carry a broad spectrum of therapeutic payloads – cytokines, antibodies, nucleic acids and more. We’ve designed these delivery vehicles to activate only on recognition of their chosen targets, unleashing their powerful cargo with exquisite precision.
We’re developing our multi-modal therapies to treat the most complex of diseases including cancer and autoimmunity.